

updated on Sept 7, 2023



Shao C. Chiang (姜紹青), Pharm.D., R. Ph.

(02) 29431640 (Home)

(02) 28970011 extension 1801 (Office)

scchiang@kfsyscc.org/ scchiang316@nycu.edu.tw

Current Position

- Assistant Professor, Department of Pharmacy, National Yang Ming Chiao Tung University, Taipei, Taiwan. (August 2023-)
- Deputy Director, Department of Pharmacy, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan. (July 2012-)

Professional Education

August 1993- May 1997	Doctor of Pharmacy Creighton University School of Pharmacy and Allied Health Professions, Omaha, Nebraska, U.S.A.
August 1986- June 1990	Bachelor of Science in Pharmacy National Taiwan University School of Pharmacy, Taipei, Taiwan.

Pharmacy Registration

March 2000 - present	Registered Pharmacist; No. 24718 The Executive Yuan of the Republic of China, The Department of Health, Taipei, Taiwan.
June 1999- 2000	Registered Pharmacist; No. 13000-040 State of Wisconsin, Department of Regulation and Licensing, Pharmacy Examining Board, Madison, Wisconsin, U.S.A.

Professional Experience

August 2001- June 2012	Clinical Coordinator, Department of Pharmacy Sun Yat-Sen Cancer Center (和信治癌中心醫 院) . No. 125, Lih-Der Road, Pei-Tou District, Taipei, Taiwan.
------------------------	--

updated on Sept 7, 2023

March 2000- July 2001

Clinical Pharmacist
Sun Yat-Sen Cancer Center. (和信治癌中心醫院) No. 125, Lih-Der Road, Pei-Tou District, Taipei, Taiwan.

January 1999-
December 1999

Oncology Pharmacy Specialty Resident
University of Wisconsin Hospital and Clinics
600 Highland Ave., Madison, WI 53792, U.S.A.

July 1997-
June 1998

Pharmacy Practice Resident
University of Wisconsin Hospital and Clinics
600 Highland Ave., Madison, WI 53792, U.S.A.

Professional Organizations

March 2022- present

Taiwan Hematology & Oncology Pharmacy Association (President)

March 2000- present

Taiwan Society of Health-System Pharmacists

March 2000- present

Taipei Pharmacist Association

December 1994- present

American Society of Health-System Pharmacists

April 1995- May 1997

Rho Chi Pharmaceutical Honor Society

Publication (Recent 5 years)

Hsu SW, Chiang SC, Hsu JC, Ko Y. Prescription patterns of granulocyte colony-stimulating factors in patients with breast cancer: A real-world study. PLoS ONE 2023;18(7): e0288642. (Co-first author)

Huang PP, Poon SYK, Chang SH, Kuo CW, Chien MW, Chen CC, Chiang SC. Improving the efficiency of medication reconciliation in two Taiwanese hospitals by using the Taiwan National Health Insurance PharmaCloud medication system. International Journal of General Medicine 2023;16: 211-220.

Poon SYK, Hsu J C, Ko Y, Chiang SC. Assessing knowledge and attitude of healthcare professionals on biosimilars: a national survey for pharmacists and physicians in Taiwan. Healthcare (Basel). 2021;9(11): 1600.

Chen HM, Chen JH, Chiang SC, Lin YC, Ko Y. An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study. Medicine. 2021;100(43): e27567.

updated on Sept 7, 2023

Chiang SC, Shen M, Lin CC, Chang HP. Establishing a protocol for the compatibilities of closed-system transfer devices with multiple chemotherapy drugs under simulated clinical conditions. PLoS One. 2021;16(9):e0257873.

Chou TC, Chiang SC, Ko Y. Health state utilities for metastatic breast cancer in Taiwan. Breast. 2020;51:57-64. (co-first author)

Chang LL, Chiang SC, Chiang MK et al. Guideline of Safe Handling for Anti-Neoplastic Hazardous Drugs- 2020. The Journal of Oncology Nursing 2020;20 suppl:5-76.

Chang LL, Chiang MK, Chiang SC, Chiu SY. Guidelines for Safe Handling of Hazardous Antineoplastic Drugs and Prevention of Exposure at Home. The Journal of Oncology Nursing 2020;20 suppl:77-84.

Chiang SC. The First Targeted Therapy toward BRCA-mutated Ovarian Cancer: Olaparib. The Journal of Oncology Nursing 2018;18(2):13-20.

Chiang SC. Atezolizumab: Program Death-1 Receptor Ligand Inhibitor Safe handling for anti-neoplastic hazardous drugs: a multidisciplinary consensus guideline in Taiwan. The Journal of Oncology Nursing 2017;17(1):5-10.

Wen TJ, Wen YW, Chien CR, Chiang SC, Hsu WW, Shen LJ, Hsiao FY. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis in chemotherapy-induced febrile neutropenia among breast cancer and Non-Hodgkin's lymphoma patients under Taiwan's national health insurance system. J Eval Clin Pract. 2017;23(2):288-293.